Start Date:10/2/2023
Start Time:9:00 AM EDT
Duration:180 minutes
LOCATION: The event will be live-streamed, and also in person: Apella Center, 450 E29th Street, New York, NY
EVENT OVERVIEW:
Praxis’ management team will joined by key opinion leaders in Movement Disorders and Epilepsy to review the Company’s portfolio as it progresses to initiating the Phase 3 program in Ulixacaltamide for Essential Tremor and advancements in the clinical Epilepsy assets.
Speakers
![](https://files.onlinexperiences.com/FileLibrary/6526/6/msouza-2021.jpg) Marcio Souza President & Chief Executive Officer Praxis Marcio Souza has served as a director and our President and Chief Executive Officer since April 2020. Prior to joining us, Mr. Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. Mr. Souza has served on the board of directors of Aeglea BioTherapeutics, Inc. since June 2021. From May 2019 to May 2020, Mr. Souza also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.
![](https://files.onlinexperiences.com/FileLibrary/6526/6/Steve0180.jpg) Steven Petrou, Ph.D. Co-Founder & Chief Scientific Officer Praxis Steven Petrou, Ph.D., is a co-founder of our company and has served as our Chief Scientific Officer since January 2018. Dr. Petrou is the Director and Head of the Department of the Florey Institute of Neuroscience and Mental Health, as well as the Head of Ion Channels and Human Disease Laboratory. Dr. Petrou is a recognized leader in the field of ion channel neuropathies in rare pediatric epilepsies and other neurodevelopmental disorders. His published interdisciplinary research has focused on functional genetics and genomics of epilepsy, elucidation of mechanisms of disease, development of several of the first animal models of genetic epilepsy and discovery and evaluation of consequent precision medicine approaches. Dr. Petrou received a B.S. in zoology and genetics and a Ph.D. in zoophysiology from the University of Melbourne.
![](https://content.onlinexperiences.com/FileLibrary/6526/6/Karl.jpg) Karl Hansen Chief Technical Operations Officer Praxis Karl Hansen, Ph.D., has served as Chief Technical Operations Officer since December 2021. Previously, he served as our Senior Vice President of CMC from May 2020 to November 2021. Prior to joining us, Dr. Hansen was at Boston Pharmaceuticals, where he served as Vice President, CMC from February 2018 to May 2020. Prior to joining Boston Pharmaceuticals, Dr. Hansen served in positions of increasing responsibility across small and large molecule process development at Amgen. Dr. Hansen serves on the executive board for the American Chemical Society Division of Organic Chemistry. Dr. Hansen received a B.S. in chemistry from the University of Delaware and a Ph.D. in organic chemistry from Harvard University.
![](https://content.onlinexperiences.com/FileLibrary/6526/6/Alex_L.jpg) Alex LaCroix Praxis Alex joined Praxis in November 2022 to lead the movement disorder program and has spent over 25 years in strategic commercial, business development, and portfolio roles in the biotechnology space. Most recently, he held a corporate development and strategy role at BioCryst Pharmaceuticals and prior to that led global business development at PTC Therapeutics where he directed transactional efforts that expanded company’s late-stage product pipeline into mitochondrial disorders and PKU. Prior to PTC, Alex held a wide range of roles based in the US and Europe at companies including Shire, Genzyme, Synageva, and Agios Pharmaceuticals where he was responsible for new product planning, product launch, and in-line brand management. At Shire, he was the global brand lead for Replagal®, supported the US launch of VPRIV®, and led the commercial assessment of Jerini Pharmaceuticals that drove the company acquisition and established the company in hereditary angioedema with Firazyr®. Alex has worked in many therapeutic areas and across multiple technology platforms. Alex has an MBA from the Carroll Graduate School of Management at Boston College and a bachelor’s degree in Latin American Studies from the University of California, Berkeley.
![](https://content.onlinexperiences.com/FileLibrary/6526/6/Alberto_Espay_head_shot_2022.png) Alberto J. Espay, MD, MSc, FAAN, FANA Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson's Disease University of Cincinnati Dr. Alberto Espay is Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson’s Disease at the University of Cincinnati. He has published over 300 peer-reviewed research articles and 10 books, including Common Movement Disorders Pitfalls, which received the Highly Commended BMA Medical Book Award in 2013, and Brain Fables, the Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them, coauthored with Parkinson patient and advocate Benjamin Stecher, selected by the Association of American Publishers for the PROSE Award honoring the best scholarly work in Neuroscience published in 2020. He has served as Chair of the Movement Disorders Section of the American Academy of Neurology, Associate Editor of the Movement Disorders journal, and on the Executive Committee of the Parkinson Study Group. Among other honors, he has received the Cincinnati Business Courier’s Health Care Hero award, the Spanish Society of Neurology’s Cotzias award, and honorary membership in the Mexican Academy of Neurology. His 2022 TEDx presentation, “Parkinson’s and Alzheimer’s: The Solution in Sight,” was selected from more than 12,000 global entries for two 2023 Telly Awards, which honor excellence in video and television across all screens. He currently serves as President of the Pan-American Section of the International Parkinson and Movement Disorders Society and directs the first biomarker study of aging (CCBPstudy.com), designed to match people with neurodegenerative disorders to available therapies from which they are most biologically suitable to benefit, regardless of clinical diagnoses.
![](https://files.onlinexperiences.com/FileLibrary/6526/6/Jackie_French_180.jpg) Jacqueline French, M.D. Professor of Neurology at NYU Grossman School of Medicine and President, Director and Founder of the Epilepsy Study Consortium
• Trained in Neurology at Mount Sinai Hospital in New York; fellowship training in EEG and epilepsy at Mount Sinai hospital and Yale University.
• Serves as the Chief Medical/Innovation Officer of the Epilepsy Foundation.
• Past president of the American Epilepsy Society; past Secretary of the American Society of Experimental Neurotherapeutics.
• Recipient of the American Epilepsy Society Lennox Award (2017) and Service Award (2005), the Epilepsy Foundation Hero award (2013), and is an ILAE Ambassador for Epilepsy.
|
First Name
|
Last Name
|
Email Address
|
Company
|
Job Title
|
Country
|
Time Zone
|
Will you be attending the event in-person?
|
|
|
|